Back to Studies
View

The Study

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial

In simple terms

This study is like a fair test where half the people got a new pill and half got a sugar pill, and they watched what happened to their kidneys for almost 4 years. They found that the new pill helped slow down how fast kidney function dropped, but it didn't stop serious kidney problems from happening. So we know it helps a little with one thing, but not with the big stuff.

80%

Analysis score

80/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting0
Methodology100
Publication100
Statistical100
Study type (basis of the score)
Randomized Controlled Trial
Level 1b - Individual RCT
What’s the bottom line?

Scientists tested a diabetes pill called oral semaglutide to see if it could stop kidneys from getting worse in people with diabetes and heart disease.

Where does this study sit?

Systematic Reviews & Meta-analyses

Max 100

Randomized Trials

Max 90

Cohort Studies

Max 72

Case-Control

Max 58

Cross-Sectional

Max 44

Case Reports & Series

Max 30

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
80

80 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.

Can establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1Slowing kidney decline by 0.4 mL/min/1.73 m² per year is meaningful over years — it may delay kidney failure, even if it didn't prevent hard outcomes like dialysis in this study.
  2. 2The pill didn't stop serious kidney problems like needing dialysis or dying from kidney issues, but it did slow down how fast kidney function dropped — by about 0.4 mL/min/1.73 m² per year.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Diabetes Care

Year

2025

Authors

J. Mann, Nikolaus Marx, J. Deanfield, S. Emerson, S. Inzucchi, Darren K. McGuire, S. Mulvagh, R. Pop-Busui, N. Poulter, M. D. Engelmann, G. Hovingh, N. Belmar, T. Idorn, O. Jeppesen, A. L. Birkenfeld, A. Amod, B. Mankovsky, Cyrus Desouza, J. J. Gorgojo-Martínez, R. Arechavaleta, Shih-Te Tu, J. Buse

Open Access
5 citations
Analysis v4
DOI:10.2337/dc25-1080
PubMed:41380027
View Source
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.